1 PREDICTORS OF MORTALITY AND CLINICAL CHARACTERISTICS AMONG

2 CARBAPENEM-RESISTANT OR CARBAPENEMASE-PRODUCING

3 ENTEROBACTERIACEAE BLOODSTREAM INFECTION IN SPANISH

- 4 CHILDREN
- 5 María Fátima Ara-Montojo¹, Luis Escosa-García PhD¹, Marina Alguacil², Nieves
- 6 Seara², Carlos Zozaya³, Diego Plaza⁴, Cristina Schuffelmann-Gutiérrez⁵, Ángela de la
- 7 Vega⁶, Carlota Fernández-Camblor⁷, Esther Ramos-Boluda⁸, María Pilar Romero-
- 8 Gómez², Guillermo Ruiz-Carrascoso PhD², Itsaso Losantos-García⁹, María José
- 9 Mellado-Peña PhD¹, Rosa Gómez-Gil².
- 10 1. Paediatric Tropical and Infectious Diseases, Department of Paediatrics, Hospital
- 11 Universitario La Paz, Madrid, Spain.
- 2. Department of Microbiology, Hospital Universitario La Paz, Madrid, Spain.
- 3. Department of Neonatology, Hospital Universitario La Paz, Madrid, Spain.
- 4. Department of Paediatric Hematology and Oncology, Hospital Universitario La Paz,
- 15 Madrid, Spain.
- 5. Paediatric Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain.
- 17 6. Department of Hepatology and Liver Transplantation, Hospital Universitario La Paz,
- 18 Madrid, Spain.
- 7. Department of Nephrology and Kidney Transplantation, Hospital Universitario La Paz,
- 20 Madrid, Spain.
- 8. Paediatric Intestinal Rehabilitation and Bowel Transplantation, Hospital Universitario
- 22 La Paz, Madrid, Spain.
- 23 9. Department of Biostatistics, Hospital Universitario La Paz, Madrid, Spain.

María Fátima Ara-Montojo and Luis Escosa-García contributed equally to this article and both should be considered first author. María Fátima Ara-Montojo. Servicio de pediatría hospitalaria, enfermedades infecciosas y tropicales. Hospital Universitario La Paz. Paseo de la Castellana 261, C.P. 28046. Madrid, Spain. Telephone number: 0034 917277479. E-mail: fatiaramon@gmail.com Luis Escosa-García. Servicio de pediatría hospitalaria, enfermedades infecciosas y tropicales. Hospital Universitario La Paz. Paseo de la Castellana 261, C.P. 28046. Madrid, Spain. Telephone number: 0034 917277479. E-mail: luisescosa1983@gmail.com Running title: "Carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infection in Spanish children" Funding: This work was not economical supported by any institution. **Transparency declarations:** None to declare.

- 51 Synopsis
- **Background:** Carbapenem-resistant Enterobacteriaceae (CRE) are a growing problem in
- 53 pediatric population worldwide with high mortality rates (18.5-52%) in bloodstream
- 54 infection (BSI).
- Objectives: The aim of this study is to evaluate predictors of 30-day mortality in CRE BSI
- in a pediatric cohort.
- 57 **Methods:** Retrospective observational single-center study (December 2005 August 2018)
- 58 was conducted. CRE BSI in children 0 to 16 years were included. Microbiological
- 59 identification (MALDI Biotyper) and antimicrobial susceptibility testing (Vitek2® and
- 60 MicroScan panel NBC44) according to current EUCAST breakpoints were performed.
- 61 PCR OXVIKP® was used to confirm carbapenemases genes (OXA-48, VIM, KPC,
- 62 NDM). Demographic characteristics, underlying diseases, source of bacteremia,
- 63 antimicrobial therapy and outcomes were collected from medical records. Survival analysis
- to establish predictors of 30 day-mortality was performed.
- Results: Thirty-eight cases were included, 76.3% hospital-acquired infections and 23.7%
- related to healthcare. All patients had underlying comorbidity and 52.6% had received a
- transplant. VIM-carbapenemase was the predominant mechanism (92%). Previous CRE
- colonization or infection rate was 52.6%. Gut (26%) and vascular catheter (21%) were the
- 69 predominant sources of infection. Crude mortality within 30 days was 18.4% (7/38);
- directly related 30-day mortality was 10.5%. Conditions associated with an increment in
- 71 30-day mortality were intensive care admission and inadequate empiric therapy (p<0.05).
- 72 Combination antibiotic targeted treatment and a low meropenem MIC were not related to
- 73 improved survival.

Conclusions: CRE BSI mortality rate is high. The most important factor related to 30-day survival in our CRE BSI cohort in children was success in empiric treatment with at least one active antibiotic.

Introduction

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

Carbapenem-resistant Enterobacteriaceae (CRE) infections are a growing problem in pediatric population worldwide. In recent years, an increment in the number of cases has been reported in many countries. ¹⁻² Some risk factors have been identified in previous studies, including underlying comorbidity, immunosuppression, previous central venous catheter, endotracheal intubation and prior antibiotic exposure. ^{3,4} CRE infections in children have been associated with high mortality rates, up to 52%, probably due to delays in appropriate antibiotic therapy, lack of available active antibiotics against CRE, underlying conditions and illness severity. ⁵ Therefore, treatment of CRE infections is a real challenge for clinicians and pediatric antibiotic pipeline is limited. Some studies in adults suggested that carbapenem-containing combination therapy was associated with improved survival in severe invasive infections due to CRE. ^{6,7} Due to the lack of studies in children, data to guide management has been extrapolated from adult literature. Current recommendation in pediatrics is combination therapy of at least two agents with in vitro activity in most scenarios, until more available data and experience with newer betalactam agents. 8-10 To improve management of CRE infections in pediatric population it is necessary to evaluate if combination therapy is associated with lower mortality rates than monotherapy for all scenarios. The aim of this study is to evaluate risk factors for CRE bacteremia and independent predictors of mortality (up to 30 days) related to the infection in a pediatric cohort.

117

118

119

Patients and Methods 121 122 Study design 123 A retrospective observational single-center study was conducted. 124 Setting 125 Hospital Universitario La Paz (HULP) Children's Hospital is a tertiary hospital with 256 126 hospitalization beds belonging to the Spanish Health National System, serving more than 127 45,000 children's emergency and more than 8,000 children's hospital admissions per year 128 in Northern Madrid (Spain). It has a 16-bed pediatric intensive care unit (PICU) and a 23-129 bed neonatal intensive care unit (NICU), being the National Referral Hospital for pediatric 130 transplantation. Inclusion and exclusion criteria 131 132 Episodes of bloodstream infection (BSI) in children 0 to 16 years of age that showed the 133 growth of CRE were included from December 2005 to August 2018. CRE isolate was 134 defined as any Enterobacteriaceae non-susceptible to meropenem (MIC > 8 mg/L), 135 imipenem (MIC > 2 mg/L) or ertapenem (MIC > 0.5 mg/L), or if carbapenemase production was documented. ¹¹ Polymicrobial bacteremia episodes were excluded. 136 137 Variables and Data Collection 138 We collected demographic characteristics, reason for admission and diagnosis, underlying 139 diseases, source of bacteremia, empirical and targeted antimicrobial therapy and outcomes 140 from medical records. Hospital's Microbiology department provided microbiological data. 141 **Definitions** 142 BSI was classified as hospital-acquired, community-acquired or healthcare-associated

(HCA) according to classic and modified CDC criteria. Episodes of community-acquired

144 bacteremia were further classified as healthcare-associated (HCA) if any of the following criteria were present: ¹² 48-hours hospital admission during the previous 90 days, receipt of 145 hemodialysis, intravenous medication or home wound care in the previous 30 days or 146 147 residence in a nursing home or long-term care facility. Classification as sepsis or septic shock was performed according to definitions of the 148 International Consensus Conference on Pediatric Sepsis. 13 149 150 The primary source of bacteremia was determined by the clinical presentation and/or by 151 the evidence of an identical strain cultured near to or on the same date as the onset of BSI 152 from other body site. To classify an infection as catheter-related BSI the 2009 Infectious Diseases Society of America (IDSA) Guidelines criteria were used. ¹⁴ When the source of 153 154 bacteremia could not be identified, it was classified as primary bacteremia. According to Hsu AJ et al. recommendations, antimicrobial therapy was considered 155 156 "microbiologically appropriate" if the patient received one active agent against the isolate 157 (MIC within the susceptible range) and "clinically adequate" if the patient received a 158 combination of two active antibiotics at a right dose and route according to source of infection. ⁸ Use of imipenem or meropenem (MIC ≤ 8 mcg/ml) was considered adequate if 159 160 high-dosed (25 mg/kg q6h for imipenem, 40 mg/kg over 3 hours q8h for meropenem), 161 adjusted to renal function, and associated with a second microbiologically active agent. 162 Bacterial isolates and microbiological work-up Blood cultures were incubated in the Bactec automated blood culture device (BACTEC TM, 163 164 Becton Dickinson, Franklin Lakes, NJ, USA) and BacT/ALERT® (bioMérieux, Marcy 165 l'Etoile, France) blood culture bottle systems. All positive blood cultures were routinely 166 subcultivated on three agar plates: sheep blood agar, chocolate blood agar and Brucella 167 blood agar.

168 Identification was performed by MALDI Biotyper (Bruker Daltonik GmbH, Bremen, 169 Germany) and antimicrobial susceptibility testing (AST) was performed using the 170 automated system Vitek2®, (bioMérieux Marcy l'Etoile, France) and MicroScan panel 171 NBC44 (Beckman Coulter) according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint. ¹⁵ Isolates were tested for extended spectrum 172 173 beta-lactamases (ESBL) production using E-test ESBL stripes (bioMérieux) and the 174 double-disk synergy test with aztreonam and amoxicillin/clavulanic acid. Isolates having a 175 MIC > 1 mg/L to imipenem or meropenem and > 0.5 mg/L to ertapenem were confirmed 176 by PCR (OXA-48, VIM, KPC, NDM specific primers) with OXVIKPND® real time PCR 177 kit (Progenie Molecular, Spain). 178 Genetic relationships between isolates were determined by multilocus-sequence typing and 179 automated repetitive-sequence-based PCR in Klebsiella pneumoniae using the 180 DiversiLab® (bioMérieux) system. 181 Outcome parameters 182 Primary outcome was death within 30 days after the first positive CRE blood culture. 183 Relationship between death and BSI episode (directly related or not directly related) was 184 established by two independent investigators, by reviewing hospital medical records. 185 Statistical analysis 186 Categorical variables were presented as absolute frequencies and percentages. Continuous 187 variables were presented as the mean or median, with its standard deviation or ranges, 188 respectively. Categorical variables were compared using chi-square test or Fisher's Exact 189 test, as appropriate. Continuous variables were compared by Student's t test or Mann-190 Whitney U test according to their distribution. Univariate analysis was conducted to 191 evaluate different possible factors related to mortality. The survival analysis was carried

192 out by means of the Kaplan-Meier analysis and "log-rank test" was performed to compare 193 survival functions. A two-tailed P value < 0.05 was considered statistically significant. All 194 statistical analysis was performed using SAS 9.3 (SAS Institute, Cary, NC, USA). 195 **Ethics** 196 HULP Institutional Review Board evaluated and approved the study protocol. All collected data were anonymized. Given its observational retrospective design, written informed 197 198 consent was waived. 199 200 **Results** 201 Clinical and epidemiological characteristics 202 Of 2842 positive blood cultures in children during the study period, 928 (32.7%) were 203 Enterobacteriaceae and 38 (1.3%) were CRE isolates that met inclusion criteria (Table 1). 204 Most cases were detected between 2010 and 2015 (73.6%). Mean age was 2.2 years (DS 205 3.2, range 0-14.5) and patients were predominantly female (55.3%). 206 No community-acquired cases were detected. Twenty-nine (76.3%) cases were hospital-207 acquired infections and 9 (23.7%) were related to healthcare. 208 In regard to underlying conditions, 20 patients (52.6%) had received a transplant. Solid 209 organ transplant was documented in 13 (9 liver, 3 multivisceral and 1 kidney), an allogenic 210 hematopoietic stem cell transplantation in 6 patients and 1 patient had received both 211 (multivisceral and allogeneic hematopoietic stem cell transplantation). Other medical 212 conditions were: heart disease (5/38, 13.2%), neurological (4/38; 10.5%), respiratory (4/38, 213 10.5%), urological (3/38, 7.9%), digestive (3/38, 7.9%) and malignancy (one hematologic 214 and one solid organ tumor). Fourteen (36.8%) patients were born prematurely.

- 215 At the time of bacteremia, 51.7% of patients with hospital-acquired disease were
- 216 hospitalized in intensive care units (8 in PICU, 7 in NICU), 41.4% in a medical ward and
- 217 6.9% were in a surgical ward (Post-Anesthesia Care Unit).
- The rate of previous antibiotic exposure, indwelling devices and other possible risk factors
- 219 for CRE infection are shown in Table 2.
- 220 Regarding the source of bacteremia, the intestinal tract was found to be the most common
- origin causing 11 cases (26.3%), followed by central venous catheter-related bacteremia in
- 8 (21.1%) and hepatobiliary origin in 6 (5.8%) patients. Three (7.9%) children had urinary
- tract infection and one patient had a peritoneal catheter-related infection. Only one patient
- had ventilator-associated pneumonia. The origin remained unknown in 8 (21.1%) cases.
- As per severity of disease, 32 (84.2%) patients with CRE BSI met systemic inflammatory
- response syndrome (SIRS) criteria of which 8 (21.1%) presented as septic shock.
- 227 Microbiological results
- 228 The isolated bacteria, resistance mechanisms and susceptibility to antimicrobials are shown
- 229 in Table 3.
- 230 *Treatment and outcomes*
- 231 Crude mortality within 30 days from onset of BSI was 18.4% (7/38). Death was considered
- 232 directly related to the BSI episode in 10.5% of total cases, based on clinical judgment.
- 233 Before antibiotic susceptibility test results, 10 (26.3%) children received microbiologically
- inappropriate empiric therapy (no active antibiotic) while the remaining 28 (73.7%)
- patients were treated with at least one active antibiotic. In 23 (60.5%) cases a carbapenem

was used before knowing antibiotic susceptibilities. Median duration of empiric treatment was 3 days (IQR 2-5). Optimal early source control was performed in 23.7% (9/38).

Thirty-six (94.7%) patients received microbiologically appropriate targeted therapy and 15 of them (39.5%) were clinically adequately treated with at least two active antibiotics, at a proper dosage and route according to the source of infection.

In univariate analysis, we found a significantly higher mortality rate in patients admitted to neonatal and intensive care units at the time of BSI onset. Including one active antibiotic in the empiric therapy showed to decrease mortality risk in a 92.4% compared to non-active antibiotic (HR 0.076; IC 95% 0.012-0.494). There was no difference in survival depending on meropenem MIC and neither between patients who received meropenem as empiric therapy and those who not. Attending targeted treatment, we did not find differences when monotherapy was used versus combination therapy and the use of meropenem did not prove to improve survival either (Table 4, Figure 1).

Discussion

In the present study, we report 38 cases of CRE bacteremia in pediatric population. To the best of our knowledge, this is the largest current pediatric cohort reported in Europe.

Novel agents (ceftazidime-avibactam, aztreonam-avibactam, cefiderocol, etc.) were not available during the study period, so only classical therapeutic agents were used. VIM-type metallo-beta-lactamases were the predominant resistance mechanism in our series, as they were present in 35 of the 38 strains. These VIM-type enzymes were first discovered in Europe in the 1990s and have been reported worldwide in the recent multidrug-resistant Enterobacteriaceae crisis, although the Mediterranean basin and the Middle East are the predominant areas. ¹⁶ Most of our cases (73.6%) were detected between 2010 and 2015,

260 due to a VIM 1 Klebsiella pneumoniae ST-54 outbreak during 2010 and an OXA-48 261 Klebsiella pneumoniae ST-11 outbreak in 2012. Antimicrobial stewardship program 262 initiatives in children emerged in 2014 in our hospital, primarily focused on PICU patients 263 so we only found one CRE BSI after 2015. 264 All episodes of infection in our study were either hospital-acquired or associated with healthcare as in other similar series. ^{3,17} Regarding risk factors of CRE BSI, we found that 265 266 those children who developed CRE BSI had multiple comorbidities, most of them (52.6%) 267 had received a transplant since our hospital is National Referral Hospital for pediatric 268 transplantation. Of note, 94.7% of patients were carriers of indwelling devices. In addition, 269 they often had exposure to carbapenems in the previous 6 months (50%). 270 The 30-day mortality rate in our study (18.4%) is not as high as compared with previous reports, ranged from 18.5 to 52%. ^{5,18-20} Grouping data from those reports and our cohort, 271 272 mortality rate is 31.8% in pediatric CRE bacteremia, although important differences 273 between series are obvious, including different resistance mechanisms or bacteremia 274 severity. For instance, our lower mortality rate could be related to the relatively low rate of 275 severe bacteremia in our series (21.1% had septic shock) and also to the fact that many 276 strains were susceptible to aminoglycosides (81.6%), offering therapeutic options. In India, 277 Nabarro et al. found a mortality rate of 52%, but resistance to aminoglycosides in their cohort was up to 90%. ⁵ In a recent study in Chinese pediatric population with 278 279 carbapenem-resistant K.pneumoniae BSI, mortality rate was similar than ours in relation to 280 low clinical severity and hematological malignancies predominance whose empirical therapy used to be more effective in covering multidrug-resistant bacteria. ¹⁸ In a meta-281 282 analysis of carbapenem-resistant K. pneumoniae infections, mortality was not shown to be 283 lower in VIM-producing compared to KPC. Therefore it is unlikely that the VIM predominant resistance mechanism in our cohort explains our lower mortality rate. ²¹ 284

empirical antibiotic therapy (no active agent), as was shown in previous studies. ²² A recent report by Lodise et al. has established that delayed appropriate therapy may be a more important driver of outcomes than CRE itself. ²³ However, Zhang et al. did not identify an association between non-active empirical antibiotic agents and mortality in children. ¹⁸ Of note, 52.6% of patients in our cohort had been colonized or infected by a CRE before, as systematic CRE colonization screening in our hospital is performed since 2010 in many units. In adults, Girmenia et al. showed a rate of CRE infection in previously colonizedpatients of 10% for immunocompetent, 25% for those with neutropenia, 26% for auto-SCT (stem cells transplant) and 39% for allo-SCT. ²⁴ In our pediatric hospital, an infection rate of 13% has been established in patients with previous VIM-type CRE colonization ²⁵, but from our knowledge no pediatric data has set which colonized children are at a higher risk to develop an infection. As many patients in our cohort were previously CRE colonized and active antibiotic in empiric therapy showed to decrease mortality risk in a 92.4% compared to non-active antibiotic, antimicrobial stewardship guided antibiogram in colonized stools from selected highly-risk patients might be an interesting strategy to improve CRE BSI prognosis. However, rapid diagnostic testing aiming to reduce the time to effective therapy in antimicrobial stewardship programs would be the most desirable approach. 26 Patients admitted to neonatal units and to intensive care units also had significant higher mortality rates in our cohort. Of note, in our survival analysis, there was no evidence of higher mortality in patients with isolated *Klebsiella* spp. strains. No source of infection showed relation to mortality either. Relationship between meropenem MIC and increased

mortality has previously been described in adults and Nabarro and Zhang also found

statistically increased mortality rate in pediatric patients with CRE BSI with a meropenem

We have found a relationship between increased 30 day-mortality and inadequate

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

MIC > 8mg/L. ^{5,18} Nevertheless, in our cohort meropenem MIC > 8 was not predictive of higher mortality. Empiric antibiotic therapy that included meropenem was also no protective in Zhang's et al. report. Regarding the use of aminoglycosides as empiric treatment, we did not found differences in mortality either.

In adults, retrospective observational studies have suggested improved survival in patients receiving combinations of two or more in vitro active antibiotics, mostly among patients with a high probability of death. ⁶ These data have been extrapolated to children with a number of authors suggesting use of combination antibiotics in CRE. ⁸ The few pediatric series so far show controversy in this aspect. In our study, targeted treatment with combinations of two or more active agents did not lead to higher survival than monotherapy, as has been shown in a recent clinical trial in adults, where combination therapy was not superior to monotherapy. ²⁷ However, most infections in Paul et al. trial (77%) were caused by *Acinetobacter baumanii* so CRE might have been underrepresented. The inclusion of meropenem in the targeted therapy also showed no survival improvement in our cohort.

Our study has some limitations. It is a retrospective study of a single cohort from just one center so the sample size is limited, although it is the largest pediatric series reported in Europe so far. This may have influenced the statistical power to identify risk factors and predictors of mortality. Moreover, the high proportion of VIM-producing Enterobacteriaceae in our cohort leads to results that may not be representative for all CRE. Regarding surveillance analysis, our low mortality rate decreases the reliability of results and we have not used severity scores. Nevertheless, given the scarcity of literature on this important subject, mostly in Western Europe, we believe it offers useful insights into the management of CRE BSI in children.

The findings of this study suggest CRE BSI are a growing problem in pediatric patients with comorbidities and underlying devices. The independent factor more related to 30-day mortality in our cohort was success in empiric treatment with at least one active antibiotic. Antimicrobial stewardship strategies focusing on the adequacy of empiric therapy are needed in CRE BSI. Combination antibiotic targeted treatment and a low Meropenem MIC were not related to improved survival in our cohort but sample size might limit these findings. **Funding** This work was not economical supported by any institution. **Transparency declarations** María Fátima Ara-Montojo and Luis Escosa-García contributed equally to this article and both should be considered first author. We have nothing to declare.

Bibliography

- 355 1. Montagnani C, Prato M, Scolfaro C, et al. Carbapenem-resistant enterobacteriaceae
- infections in children: An Italian retrospective multicenter study. *Pediatr Infect Dis*
- 357 J. 2016;35(8):862-868. doi:10.1097/INF.000000000001188
- 2. Logan LK, Renschler JP, Gandra S, Weinstein RA LR. Carbapenem-Resistant
- Enterobacteriaceae in Children, United States, 1999–2012. Emerg Infect Dis.
- 360 2015;21(11):2014-2021. doi:10.3201/eid2111.150548
- 361 3. Díaz A, Ortiz DC, Trujillo M, Garcés C, Jaimes F, Restrepo AV. Clinical
- characteristics of carbapenem-resistant Klebsiella pneumoniae infections in ill and
- colonized children in Colombia. *Pediatr Infect Dis J.* 2016;35(3):237-241.
- 364 doi:10.1097/INF.0000000000000987
- 365 4. Chiotos K, Tamma PD, Flett KB, et al. Multicenter study of the risk factors for
- 366 colonization or infection with carbapenem-resistant Enterobacteriaceae in children.
- 367 Antimicrob Agents Chemother. 2017;61(12):1-9. doi:10.1128/AAC.01440-17
- 368 5. Nabarro LEB, Shankar C, Pragasam AK, et al. Clinical and Bacterial Risk Factors
- for Mortality in Children with Carbapenem-resistant Enterobacteriaceae
- 370 Bloodstream Infections in India. *Pediatr Infect Dis J.* 2017;36(6):e161-e166.
- 371 doi:10.1097/INF.000000000001499
- 372 6. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate
- combination therapy on mortality of patients with bloodstream infections due to
- 374 carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective
- 375 cohort study. Lancet Infect Dis. 2017;17(7):726-734. doi:10.1016/S1473-
- 376 3099(17)30228-1

- 7. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella
- pneumoniae bloodstream infections: Lowering mortality by antibiotic combination
- schemes and the role of carbapenems. *Antimicrob Agents Chemother*.
- 380 2014;58(4):2322-2328. doi:10.1128/AAC.02166-13
- 8. Hsu AJ, Tamma PD. Treatment of multidrug-resistant gram-negative infections in
- 382 children. Clin Infect Dis. 2014;58(10):1439-1448. doi:10.1093/cid/ciu069
- 383 9. Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of Carbapenem-Resistant
- Enterobacteriaceae Infections in Children. 2019;(Xx Xxxx):1-11.
- 385 doi:10.1093/jpids/piz085
- 386 10. Aguilera-Alonso D1, Escosa-García L2, Saavedra-Lozano J3, Cercenado E4 B-AF.
- 387 Carbapenem-Resistant Gram-Negative Bacterial Infections in Children. *Antimicrob*
- 388 Agents Chemother. 2020;64(3). doi:10.1128/AAC.02183-19
- 389 11. Centers for Diasease Control and Prevention. CDC. Facility Guidance for Control of
- 390 Carbapenem-resistant Enterobacteriaceae (CRE). Natl Cent Emerg Zoonotic Infect
- 391 *Dis.* 2014;(November):24.
- 392 https://www.osha.gov/SLTC/ebola/control_prevention.html.
- 393 12. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP et al.
- Health care--associated bloodstream infections in adults: a reason to change the
- accepted definition of community-acquired infections. Ann Intern Med [Internet].
- 396 2002;137(10):791-797. doi:10.7326/0003-4819-137-10-200211190-00007
- 397 13. Glodstein, B., Giroir, B., & Randolph A. International pediatric sepsis consensus
- 398 conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit*
- 399 *Care Med.* 2005;6(1):96.

- 400 14. FA M. IDSA guidelines for the diagnosis and management of intravascular catheter-
- related bloodstream infection. *Clin Infect Dis.* 2009;49(11):1770-1771.
- 402 doi:10.1086/648112
- 403 15. EUCAST Breakpoint tables v 8.1. http://www.eucast.org/clinical_breakpoints/.
- 404 Published 2018.
- 405 16. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: A last frontier
- 406 for β-lactams? *Lancet Infect Dis.* 2011;11(5):381-393. doi:10.1016/S1473-
- 407 3099(11)70056-1
- 408 17. Malande OO, Du Plessis A, Rip D, Bamford C, Eley B. Invasive carbapenem-
- resistant Enterobacteriaceae infection at a paediatric hospital: A case series. *South*
- 410 African Med J. 2016;106(9):877. doi:10.7196/SAMJ.2016.v106i9.11028
- 411 18. Zhang Y, Guo LY, Song WQ, Wang Y, Dong F, Liu G. Risk factors for
- 412 carbapenem-resistant K. pneumoniae bloodstream infection and predictors of
- 413 mortality in Chinese paediatric patients. *BMC Infect Dis.* 2018;18(1):1-10.
- doi:10.1186/s12879-018-3160-3
- 415 19. Maltezou HC, Kontopidou F, Katerelos P, Daikos G, Roilides E, Theodoridou M.
- Infections caused by carbapenem-resistant gram-negative pathogens in hospitalized
- 417 children. *Pediatr Infect Dis J.* 2013;32(4):151-154.
- doi:10.1097/INF.0b013e3182804b49
- 419 20. Ozsurekci Y, Aykac K, Cengiz AB, et al. Bloodstream infections in children caused
- by carbapenem-resistant versus carbapenem-susceptible gram-negative
- 421 microorganisms: Risk factors and outcome. *Diagn Microbiol Infect Dis*.
- 422 2017;87(4):359-364. doi:10.1016/j.diagmicrobio.2016.12.013

- 423 21. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients
- 424 infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol
- 425 *Antimicrob*. 2017;16(1):1-12. doi:10.1186/s12941-017-0191-3
- 426 22. Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant Klebsiella pneumoniae
- in high-risk haematological patients: Factors favouring spread, risk factors and
- outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias. *BMC Infect*
- 429 Dis. 2017;17(1):1-12. doi:10.1186/s12879-017-2297-9
- 430 23. Lodise T, Sciences H, Bonine NG, et al. Antimicrobial Resistance or Delayed
- Appropriate Therapy—Does One Influence Outcomes More Than the Other among
- Patients with Serious Infections due to Carbapenem-Resistant Versus Carbapenem-
- Susceptible Enterobacteriaceae? *Open Forum Infect Dis.* 2019;ofz194(Major
- 434 Article).
- 435 24. Girmenia C, Rossolini GM, Piciocchi A, et al. Infections by carbapenem-resistant
- 436 Klebsiella pneumoniae in SCT recipients: A nationwide retrospective survey from
- 437 Italy. Bone Marrow Transplant. 2015;50(2):282-288. doi:10.1038/bmt.2014.231
- 438 25. González-rubio R, Parra-blázquez D, San-juan-sanz I, Ruiz-carrascoso G, Gallego
- S, Escosa-garcía L. Original Evolución de la incidencia de pacientes con
- 440 colonización e infección por bacterias productoras de carbapenemasas VIM en un
- hospital pediátrico en España. 2019;32(1):60-67.
- 442 26. Timbrook TT, Morton JB, Mcconeghy KW, Caffrey AR, Mylonakis E, Laplante
- 443 KL. The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in
- Bloodstream Infections : A Systematic Review and Meta-analysis. 2017;64:15-23.
- 445 doi:10.1093/cid/ciw649

446	27.	Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus
447		meropenem for treatment of severe infections caused by carbapenem-resistant
448		Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect
449		Dis. 2018;18(4):391-400. doi:10.1016/S1473-3099(18)30099-9
450		
451		
452		
453		
454		
455		
456		
457		
458		
459		
460		
461		
462		
463		
464		
465		
466		

	Age at admission	Sex	Department	Bacteremia	Microorganism	Source	Carbapenem Resistance	ESBL	Exitus at 30th day	Sepsis /shock	Days form admission to BSI	Days from BSI to discharge / death	Empirical Treatment (ACTIVE AGAINST GRAM NEGATIVE BACTERIA)	Targeted Treatment
1	5 m	F	Post-anesthesia Care Unit	НА	K. pneumoniae	Gut	VIM	?	A	?	106	392	Meropenem	Meropenem + Amikacin + Ciprofloxacin
2	4 m	M	Post-anesthesia Care Unit	HA	K. pneumoniae	Catheter related	VIM		†		22	3	Meropenem + Amikacin	Meropenem + Amikacin
3	4 y	M	Hepatology Ward	HCA	K. oxytoca	Hepatobiliar	VIM		A	?	0	21	Cefotaxime	Meropenem + Amikacin
4	5 m	M	PICU	HA	C. freundii	Hepatobiliar	VIM		A		17	95	Meropenem + Amikacin	Meropenem + Amikacin
5	14 m	F	Hepatology Ward	HA	K. pneumoniae	Hepatobiliar	VIM	?	A	?	110	152	Meropenem	Meropenem + Amikacin
6	3 y	F	PICU	HA	K. pneumoniae	Hepatobiliar	VIM	?	A	?	51	30	Gentamicin + Ciprofloxacin	Ciprofloxacin
7	3 m	M	PICU	HA	K. pneumoniae	Catheter related	VIM		A	?	29	5	None	Amikacin
8	3 y	F	Hepatology Ward	HA	S. ureilytica	Gut	VIM	?	A		126	23	Cefepime + Colistin	Ciprofloxacin
9	4 m	M	Neonatal Unit	HA	K. pneumoniae	Unknown	VIM		†	2	109	22	Meropenem + Amikacin	Meropenem + Amikacin
10	2 m	F	Neonatal Unit	HA	K. pneumoniae	Unknown	Porins resistance	?	A	2	355	70	Meropenem	Meropenem + Amikacin
11	18 d	M	Neonatal Unit	HA	K. pneumoniae	Gut	VIM		†	2	2	3	Cefotaxime + Meropenem	
12	59 d	F	Neonatal Unit	HA	K. pneumoniae	Unknown	OXA-48	?	†	2	59	22	Cefotaxime	Amikacin
13	5 m	M	Neonatal Unit	HA	E. cloacae	Gut	VIM		A	?	150	22	Amikacin	Amikacin
14	75 d	M	Neonatal Unit	HA	K. pneumoniae	UTI	OXA-48	?	A	?	75	226	Meropenem	Meropenem + Amikacin
15	6 m	M	PICU	НА	S. marcescens	Pulmonary	VIM		A		4	18	Cefotaxime	Cefotaxime + Gentamicin + Aztreonam
16	17 m	F	Haemato-oncology Ward	HA	S. marcescens	Unknown	VIM		A	2	8	17	Meropenem + Amikacin	Meropenem + Amikacin
17	7 m	F	Haemato-oncology Ward	HA	k. pneumoniae	Unknown	VIM		A		21	375	Meropenem + Amikacin	Meropenem + Amikacin
18	14 y	M	Haemato-oncology Ward	HA	E. cloacae	Unknown	VIM	?	A	2	60	31	Cefepime + Meropenem	Amikacin + Ciprofloxacin
19	10 y	F	Haemato-oncology Ward	HA	E. cloacae	Gut	VIM		A	?	36	17	Meropenem + Cefepime	Meropenem + Ciprofloxacin
20	3 y	M	Haemato-oncology Ward	HA	K. oxytoca	Gut	VIM	?	A		1	7	Cefixime, Cefotaxime	Ciprofloxacin
21	7 m	M	General Paediatrics Ward	HA	K. pneumoniae	Catheter related	VIM	?	A	2	19	21	Meropenem	Ciprofloxacin
22	8 m	F	PICU	HA	K. pneumoniae	Peritonitis	VIM	?	A	?	143	4	Meropenem	Meropenem + Colistin
23	4 y	F	Haemato-oncology Ward	HA	E. cloacae	Unknown	VIM		A	?	60	42	Cefepime + Amikacin	Ciprofloxacin + Amikacin
24	4 y	M	Gastroenterology Ward	HCA	E. coli	Catheter related	VIM		A	?	0	38	Meropenem + Amikacin	Meropenem + Amikacin
25	2 y	M	Nephrology Ward	HA	K. pneumoniae	UTI	VIM	2	A	?	6	12	Amikacin + Ceftazidime	Amikacin + Ciprofloxacin
26	2 y	M	Hepatology Ward	НА	E. cloacae	Hepatobiliar	VIM		A	2	48	176	Meropenem + Amikacin	Amikacin + Ciprofloxacin
27	2 y	F	PICU	НА	E. cloacae	Pulmonary	VIM		A	?	26	45	Meropenem + Amikacin	Meropenem + Amikacin +
28	10 m	F	Gastroenterology	HCA	E. aerogenes	Catheter	VIM		A	?	1	22	Meropenem +	Ciprofloxacin Gentamicin +
29	6 m	M	Ward PICU	HA	K. pneumoniae	related Hepatobiliar	VIM	2	A	2	63	64	Gentamicin Meropenem + Colistin	Aztreonam Colistin + Fosfomycin

30	4 y	M	Gastroenterology	HCA	K. pneumoniae	Catheter	VIM		A	?	0	50	Amikacin	Amikacin +
			Ward			related								Aztreonam
31	15 m	M	Nephrology Ward	HCA	K. pneumoniae	Peritoneal	VIM		A	?	1	8	Meropenem +	Amikacin +
						dyalisis							Amikacin	Aztreonam
						catheter								
32	16 y	M	PICU	HCA	K. pneumoniae	Gut	VIM		†	?	4	2	Cefepime +	Colistin +
													Amikacin +	Aztreonam +
													Colistin	Fosfomycin
33	4 y	M	General Pediatrics	HCA	K. pneumoniae	Gut	VIM		A	?	0	16	Meropenem +	Amikacin
			Ward										Amikacin	
34	22 m	M	Haemato-oncology	HA	K. pneumoniae	Catheter	VIM	2	A	?	226	41	Meropenem	Imipenem +
			Ward			related								Amikacin +
														Ciprofloxacin
35	2 y	F	Haemato-oncology	HCA	K. pneumoniae	Catheter	VIM		A	?	0	14	Cefepime	Amikacin +
			Ward			related								Ciprofloxacin
36	9 y	F	PICU	HA	K. oxytoca	Gut	VIM		†	?	50	2	Meropenem +	Meropenem +
													Amikacin	Ciprofloxacin +
														Colistin
37	10 m	F	Emergency	HCA	K. oxytoca	UTI	VIM		A	?	-1	5	Amikacin +	Cotrimoxazole
			Department										Fosfomycin	
38	5 m	F	Neonatal Unit	HA	S. marcescens	Unknown	VIM		†	?	175	30	Ciprofloxacin	Ciprofloxacin

TABLE 1. Clinical features of patients with bacteremia due to CRE. Months (m), female (F), hospital-acquired (HA), alive (A), exitus (†), male (M), years (y), health care associated (HCA), days (d), urinary tract infection (UTI).

Risk factor	N (%) 491 Total N: 38
Any antibiotic exposure (30 previous days)	32 (84.2)492
Cephalosporin exposure (30 previous days)	19 (50) 493
Carbapenem exposure (6 previous months)	19 (50)
Admission to a unit with previous CRE cases (12 previous months)	14 (36.8)494
Previous colonization or infection by CRE	20 (52.6) 495
Surgery	18 (47.4) 496
Central venous catheter	35 (92.1)
Urinary catheter	20 (52.6) 497
Drainage tube	12 (31.5) 498
Parenteral nutrition	26 (77)
Mechanical ventilation	18 (47.4) 499
Neutropenia	5 (13.2) 500
Renal failure	9 (23.7)
	501

TABLE 2. Risk factors related to CRE bacteremia.

Ct.	rain
Su	rain

		AZT	ERT	IMI	MER	COL	AK	CIP	TYG	FOS
K. pneumoniae VIM	Range MIC	≤1 ->8	1 ->1	2 ->8	≤1 ->8	≤0.5->4	≤2 ->32	≤0,5 ->2	≤1 ->4	≤32->64
(18)	S (%)	50	0	11.1	44.4	83.3	72.2	61.1	77.7	83.3
K. pneumoniae OXA-48	Range MIC	>16	>1	2-8	2-8	≤0.5	≤2	>2	4	>64
ESBL (2)	S (%)	0	0	50	50	100	100	0	0	0
K. pneumoniae ESBL	MIC	>16	>1	8	8	≤0.5	≤2	>2	≤1	≤16
(1)	S (%)	0	0	0	0	100	100	0	100	100
E. cloacae VIM (6)	Range MIC	≤1 ->8	≤0.5->1	4 - >8	≤1 ->8	≤0.5 ->4	≤2	≤0.5 - 1	≤1	≤16
	S (%)	66.6	50	16.6	50	66.6	100	66.6	100	83.3
K. oxytoca VIM (4)	Range MIC	≤1->32	>32	≤1->8	≤1->8	≤0.5	≤2->32	≤0,5	≤1	≤32->64
	S (%)	50	0	25	50	100	75	100	100	25
S. marcescens VIM	Range MIC	≤1	>1	>8	>8	>2	≤2	≤0,5	≤1	≤32->64
(3)	S (%)	100	0	0	0	0	100	100	66.6	66.6
E.coli VIM (1)	MIC	≤1	1	8	8	≤0.5	≤2	≤0.5	≤1	32
	SIR	S	I	I	I	S	S	S	S	S
C. freundii VIM	MIC	≤1	>1	>8	>8	≤0.5	≤2	≤0.5	≤1	≤16
(1)	SIR	S	R	R	R	S	S	S	S	S
S. ureilytica VIM	MIC	>8	1	>8	2	>4	≤2	≤0,5	≤1	32
(1)	SIR	R	I	R	S	R	S	S	S	S
E. aerogenesa VIM	MIC	>8	1	>8	2	>4	≤2	≤0,5	≤1	32
(1)	SIR	R	I	R	S	R	S	S	S	S
ALL (38)	S (%) I (%)	55.3 2.6	7.9 7.9	13.2 36.8	39.5 34.2	73.6	84.2	68.4	81.6 7.9	71.1
	R (%)	42.1	84.2	50	26.3	26.3	15.8	31.6	10.5	28.9

 TABLE 3. Resistance of strains to antimicrobials agents. "MIC" is the Minimum Inhibitory


517 Concentration acquired in mg/L; "Range MIC" is the range of Minimum Inhibitory Concentration; "S" stands

for susceptible; "I" for intermediate and "R" for resistant, as interpreted according to the EUCAST V 6.0

 $519 \qquad \text{guidelines. "AZT" for aztreonam, "ERT" for ertapenem, "|M|" for imipenem, "MER" for meropenem, "COL" } \\$

for colistin, "AK" for amikacin", "CIP" for ciprofloxacin, "TYG" for tygecicline, "FOS" for fosfomycin.

Variable	Survived N=31 (%)	Died N=7 (%)	Hazard ratio (95% CI)	P
Median Age (months)	17.64	4.32		
Male (%)	54.84	57.14		
Klebsiella isolated	19 (61.29)	6 (85.71)		NS
Source of infection: Intestinal or hepatobiliary tracts	13 (41.94)	3 (42.86)		NS
Catheter-related	7 (22.58)	1 (14.29)		NS
Urinary tract	3 (9.68)	0 (0)		NS
Pulmonary	2 (6.45)	0 (0)		NS
Peritoneal catheter	1 (3.23)	0 (0)		NS
Unknown	5 (16.13)	3 (42.86)		NS
Neonatal unit admission	3 (9.68)	4 (57.14)	0.197 (0.111-0.956)	0.017
Intensive care unit admission	10 (32.26)	6 (85.71)	0.13 (0-0.984)	0.024
Presentation as sepsis	26 (83.87)	6 (85.71)		NS
Presentation as septic shock	5 (16.13)	3 (42.86)		NS
Meropenem MIC >8 mg/L	8 (25.81)	2 (28.57)		NS
Optimal early source control	8 (25.81)	1 (14.29)		NS
No-active antibiotic in empiric therapy	6 (19.35)	4 (57.14)	0.076 (0.012-0.494)	0.001
Meropenem in empiric therapy	19 (61.29)	4 (57.14)		NS
Aminoglycoside in empiric therapy	15 (48.39)	4 (57.14)		NS
Non-clinically adequately or improvable target therapy	19 (61.29)	3/6 (50)*		NS
Monotherapy in target treatment	16 (51.61)	3/6 (50)*		NS
Meropenem in target therapy	14 (45.16)	4/6 (66.66)*		NS



- FIGURE 1. Kaplan-Meier curves of different factors and survival at 30 days in patients with CRE
- 537 bacteremia. Non-significant (NS); Minimum Inhibitory Concentration (MIC)